What is the Relay Therapeutics Inc. stock price forecast?

Relay Therapeutics Inc. is currently trading at $18.37. View real-time AI analysis on Alpha Lenz.

What is Relay Therapeutics Inc. insider trading activity?

View the latest insider trading data for Relay Therapeutics Inc. on Alpha Lenz.

What is Relay Therapeutics Inc.'s P/E ratio?

Relay Therapeutics Inc.'s P/E ratio is -11.4.

Relay Therapeutics Inc.

NASDAQ · RLAY

$18.37+0.08(+0.44%)Pre-market

Ask about Relay Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Relay Therapeutics Inc. trades at a P/E of -11.4 (undervalued) with modest ROE of -41.1%. 3Y revenue CAGR of 123.2% highlights clear growth momentum.”

Ask for details →

Company Overview

Relay Therapeutics Inc. is a biotechnology company focused on transforming the drug discovery process through cutting-edge technology. Committed to addressing complex diseases, Relay Therapeutics leverages an innovative approach called dynamic protein motion analysis, which seeks to better understand how proteins move and function within the human body. This advanced technique enables the company to develop more precise and efficient therapeutics, particularly in the field of oncology, where it aims to create targeted treatments for various forms of cancer. Additionally, Relay Therapeutics extends its research efforts into genetic diseases, seeking to bring new hope to patients through breakthrough therapies. By integrating computational and experimental techniques, Relay Therapeutics positions itself at the forefront of biotechnology innovation. As a market player, the company contributes significantly to the biotech sector's efforts to advance personalized medicine, improving outcomes by tailoring treatments to individual patient profiles.

CEODr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Websitehttps://www.relaytx.com

SectorHealthcare

IndustryBiotechnology

Employees197

Company Statistics

FY 2025

Profile

$3.15BMarket Cap

$15.36MRevenue

0.00Shares Out

197Employees

Margins

N/AGross

-1948.43%EBITDA

-1971.59%Operating

-1800.58%Pre-Tax

-1800.58%Net

Valuation

-11.40P/E

5.56P/B

205.28EV/Sales

-10.36EV/EBITDA

-13.36P/FCF

Growth (CAGR)

123.20%Rev 3Yr

-28.58%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-37.05%ROA

-41.12%ROE

-40.56%ROIC

Financial Health

$84.02MCash & Cash Equivalents

$-29.75MNet Debt

9.57%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Relay Therapeutics Inc. trades at a P/E of -11.4 (undervalued) with modest ROE of -41.1%. 3Y revenue CAGR of 123.2% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Relay Therapeutics Inc. (ticker: RLAY) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 197 employees. Market cap is $3.2B.

The current price is $18.37 with a P/E ratio of -11.4x and P/B of 5.56x.

ROE is -41.12% and operating margin is -1971.59%. Annual revenue is $15M.